Conference Proceedings

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

Eliza Anne Hawkes, Sze Ting Lee, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, Colm Keane, David Ritchie, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Allison Barraclough

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021

Abstract

7560 Background: Standard of care immunochemotherapy in front-line (1L) follicular lymphoma (FL) is highly efficacious but not without significant toxicity. High rates of grade 3-5 adverse events (AEs), primarily infection and bone marrow suppression, are experienced in up to 75% of patients. A more tolerable but equally effective approach is required. PD-1 inhibition, in combination with rituximab (R), increases T cell anti-tumour effect & enhances NK cell antibody dependent cell cytotoxicity, with proven efficacy in relapsed FL. The concept of ‘priming’ the immune system with nivolumab (N) prior to tumour-directed therapy has rationale and evidence, but the safety of this approach in 1L F..

View full abstract